Welcome to our dedicated page for Precision Biosciences news (Ticker: DTIL), a resource for investors and traders seeking the latest updates and insights on Precision Biosciences stock.
Overview of Precision BioSciences, Inc. (DTIL)
Precision BioSciences, Inc., headquartered in Durham, North Carolina, is a biotechnology company specializing in genome editing. At the heart of its operations is its proprietary genome editing platform, ARCUS, a highly advanced and versatile tool designed to address complex challenges in human health and agriculture. Precision BioSciences aims to leverage its cutting-edge technology to develop innovative solutions that improve lives and create sustainable food systems.
The ARCUS Genome Editing Platform
The ARCUS platform is the cornerstone of Precision BioSciences' business model. ARCUS is derived from a naturally occurring genome-editing enzyme called I-CreI, which has been engineered to create a highly specific and efficient editing tool. One of ARCUS's unique advantages is its relatively small size, which allows for delivery to a wider range of cells and tissues through both viral and non-viral methods. This flexibility is critical for addressing a diverse array of genetic disorders and agricultural challenges. By enabling precise edits to DNA, ARCUS provides a foundation for developing therapies that target the root causes of genetic diseases.
Applications in Human Health
Precision BioSciences is actively utilizing ARCUS to develop therapeutic candidates aimed at treating severe and complex diseases. Its focus areas include genetic disorders, cancers, and other conditions where genome editing can offer transformative solutions. The company's therapeutic pipeline is designed to address unmet medical needs, with an emphasis on safety, efficacy, and accessibility. By collaborating with strategic partners and leveraging its in-house expertise, Precision BioSciences is working to bring groundbreaking treatments to patients worldwide.
Applications in Agriculture
In addition to its healthcare initiatives, Precision BioSciences applies ARCUS to agricultural challenges, aiming to create sustainable and resilient food systems. The technology is used to develop crops with enhanced traits such as improved yield, disease resistance, and environmental adaptability. This dual focus on health and agriculture sets Precision BioSciences apart from many of its competitors, showcasing the versatility and scalability of the ARCUS platform.
Competitive Landscape
Precision BioSciences operates in a highly competitive biotechnology sector, alongside companies like CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics. Its differentiation lies in the unique attributes of the ARCUS platform, particularly its small size and precise editing capabilities. These features potentially enable broader therapeutic applications and delivery options compared to other genome editing technologies. The company's dual focus on human health and agriculture further distinguishes it, providing diversified opportunities for innovation and revenue generation.
Challenges and Market Position
Like many biotechnology companies, Precision BioSciences faces challenges such as high research and development costs, stringent regulatory requirements, and the need to demonstrate clinical and commercial success. However, its proprietary technology, strategic partnerships, and diversified applications position it as a promising player in the genome editing space. By addressing critical issues in healthcare and agriculture, Precision BioSciences is contributing to advancements that have the potential to create significant societal impact.
Conclusion
Precision BioSciences, Inc. is a pioneering biotechnology company that combines scientific innovation with practical applications to address some of the world's most pressing challenges. Through its ARCUS platform, the company is advancing the fields of genome editing, therapeutics, and agriculture, positioning itself as a versatile and impactful player in its industry. Its commitment to precision, safety, and efficacy underscores its mission to improve life through science.
Precision BioSciences (DTIL) has reported promising updates on its allogeneic CAR T cell therapies, PBCAR0191 and PBCAR19B. In a Phase 1/2a study, PBCAR0191 showed a 73% overall response rate and a 59% complete response rate among heavily pre-treated patients. Notably, 100% of patients who had prior autologous CAR T therapy responded to PBCAR0191. The company is also progressing with PBCAR19B, which aims to be a best-in-class CD19 therapy. As of November 30, 2021, Precision holds approximately $152 million in cash, supporting operations into 2023.
Precision BioSciences, Inc. (DTIL) announced an upcoming webcast on December 11, 2021, at 7:30 PM ET to review interim data on the PBCAR0191 CD19 allogeneic CAR T program presented at the American Society of Hematology Annual Meeting. Key oral presentations include details on the efficacy of PBCAR0191 in relapsed/refractory B-cell malignancies, showcasing its therapeutic potential. The company aims to provide updates on its CAR T pipeline during this event, emphasizing its commitment to developing innovative gene editing therapies.
Precision BioSciences (NASDAQ: DTIL) announced the presentation of preclinical data on its chronic hepatitis B virus (HBV) program at the HEP DART 2021 conference in Cabo San Lucas, Mexico, from December 5-9, 2021.
The oral presentation, titled "Targeting Hepatitis B cccDNA with a Sequence-Specific ARCUS Nuclease to Eliminate Hepatitis B Virus In Vivo", is scheduled for December 6, 2021, at 11:25 AM ET. Preclinical research demonstrated that ARCUS technology reduced HBV s-antigen levels by 77% in infected human hepatocytes and achieved a durable 96% reduction in mouse models.
Precision BioSciences announced key leadership changes with Michael Amoroso appointed as President and CEO. The company is focusing on advancing its ARCUS gene editing platform, targeting three investigational new drug applications within three years. Financial results showed a revenue increase to $24 million for Q3 2021, up from $7.4 million in Q3 2020, primarily due to an agreement with iECURE. Despite increased R&D expenses at $25.9 million, the net loss narrowed to $11.3 million from $26 million year-over-year, showcasing operational progress.
Precision BioSciences (NASDAQ: DTIL) announced the acceptance of its abstract titled “Allogeneic CAR T cells with Deoxycytidine Kinase Knockdown Demonstrate Resistance to Fludarabine” for presentation at the SITC 36th Annual Meeting from November 10-14, 2021, in Washington, D.C. The study highlights a preclinical advancement using ARCUS gene editing to develop fludarabine-resistant CAR T cells, with a notable 70% reduction in dCK mRNA and improved tumor clearance in mice. The findings may enhance the potential of CAR T therapies in treating cancers resistant to conventional treatments.
Precision BioSciences (NASDAQ: DTIL) announced the addition of two experienced directors, Sam Wadsworth, Ph.D. and Shari Lisa Piré, J.D., to its Board. These appointments enhance the board's expertise in gene therapy and operational leadership. Dr. Wadsworth has nearly 30 years of experience in gene therapy development, while Ms. Piré brings extensive legal and business transformation skills. The company aims to advance three INDs/CTAs in the next three years, marking a significant phase in its growth strategy.
Precision BioSciences (NASDAQ: DTIL) has announced encouraging results from its Phase 1/2a study of PBCAR0191, targeting relapsed/refractory non-Hodgkin’s lymphoma (NHL) and B-cell acute lymphoblastic leukemia (B-ALL). Enhanced lymphodepletion strategy improved the overall response rate (83%) and complete response rate (CR) among heavily pretreated subjects. Data will be presented at the ASH Annual Meeting on December 11-14, 2021. Notably, 80% of B-ALL patients responded positively, indicating potential for bridging to stem cell transplant.
Precision BioSciences, Inc. (DTIL) announced it will publish its financial results for Q3 2021 on November 10, 2021, and provide a business update. CEO Michael Amoroso will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on November 16, 2021. The company utilizes its ARCUS® genome editing platform for developing CAR T and in vivo gene editing therapies targeting genetic and infectious diseases. Investors can access a live webcast of the chat on the company’s website.
Precision BioSciences, Inc. (NASDAQ: DTIL) announced that Dr. Derek Jantz, Chief Scientific Officer and Co-Founder, will present at the Jefferies Virtual Gene Therapy/Gene Editing Summit on
Precision BioSciences, a clinical-stage biotech company (NASDAQ: DTIL), announced an inducement grant for Michael Amoroso, its new President and CEO. The grant includes options to purchase 850,000 shares and restricted stock units valued at $237,000. The stock option has a 10-year term, with 25% vesting on October 15, 2022, and the remainder vesting quarterly over three years. Both awards comply with the company's 2021 Employment Inducement Incentive Award Plan, approved by the Compensation Committee.
FAQ
What is the current stock price of Precision Biosciences (DTIL)?
What is the market cap of Precision Biosciences (DTIL)?
What is Precision BioSciences' core technology?
What industries does Precision BioSciences operate in?
How does the ARCUS platform differentiate Precision BioSciences from competitors?
What are the main applications of ARCUS in healthcare?
Does Precision BioSciences have applications outside of healthcare?
Who are Precision BioSciences' main competitors?
What challenges does Precision BioSciences face?
What makes Precision BioSciences unique in the biotechnology industry?
How does Precision BioSciences generate revenue?
What is the significance of ARCUS's small size?
